- BriaCell Therapeutics Corp BCTX has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer.
- The company anticipates commencing clinical trials for these novel therapies in 2022.
- Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to commence patient dosing in 2021.
- Price Action: BCTX shares are up 11.1% at $6.70 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
